2016•Value in HealthOpen access

Cost Analysis Of Patients With Multiple Sclerosis Newly Initiating Subcutaneous Interferon β-1a Versus Oral Disease-Modifying Drugs

C Kozma, FE Munschauer, AL Phillips

Open full text 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Teriflunomide, Fingolimod, Dimethyl fumarate, Medicine, Multiple sclerosis, Internal medicine, Glatiramer acetate, Disease

Back to paper search Browse research topics Original source

Cost Analysis Of Patients With Multiple Sclerosis Newly Initiating Subcutaneous Interferon β-1a Versus Oral Disease-Modifying Drugs — Research Paper | ScholarLens